- Home
- YI vs ONCY Comparison
YI vs ONCY Comparison
Compare YI & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- ONCY
- Stock Information
- Founded
- YI 2010
- ONCY 1998
- Country
- YI China
- ONCY Canada
- Employees
- YI N/A
- ONCY N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- ONCY Pharmaceuticals and Biotechnology
- Sector
- YI Consumer Staples
- ONCY Health Care
- Exchange
- YI Nasdaq
- ONCY Nasdaq
- Market Cap
- YI 56.5M
- ONCY 49.2M
- IPO Year
- YI N/A
- ONCY 1999
- Fundamental
- Price
- YI $7.50
- ONCY $0.56
- Analyst Decision
- YI
- ONCY Strong Buy
- Analyst Count
- YI 0
- ONCY 3
- Target Price
- YI N/A
- ONCY $4.33
- AVG Volume (30 Days)
- YI 24.0K
- ONCY 330.3K
- Earning Date
- YI 05-22-2025
- ONCY 05-08-2025
- Dividend Yield
- YI N/A
- ONCY N/A
- EPS Growth
- YI N/A
- ONCY N/A
- EPS
- YI N/A
- ONCY N/A
- Revenue
- YI $1,973,017,082.00
- ONCY N/A
- Revenue This Year
- YI N/A
- ONCY N/A
- Revenue Next Year
- YI N/A
- ONCY N/A
- P/E Ratio
- YI N/A
- ONCY N/A
- Revenue Growth
- YI N/A
- ONCY N/A
- 52 Week Low
- YI $0.41
- ONCY $0.47
- 52 Week High
- YI $11.35
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- YI 46.64
- ONCY 45.75
- Support Level
- YI $6.07
- ONCY $0.47
- Resistance Level
- YI $7.74
- ONCY $0.65
- Average True Range (ATR)
- YI 0.65
- ONCY 0.05
- MACD
- YI -0.10
- ONCY 0.01
- Stochastic Oscillator
- YI 50.53
- ONCY 50.00
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.